EyeGate Awarded New U.S. Patent for Iontophoretic Delivery of Corticosteroids to the Eye

Further Strengthens Global IP Protection for EGP-437 WALTHAM, Mass., Dec. 19, 2017 — EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical […]

read more

EyeGate Achieves 75% Enrollment in Pivotal Phase 3 Clinical Trial for Anterior Uveitis Triggering Milestone Payment

On track to report topline data in 2Q18 and file NDA within 2018 WALTHAM, Mass., Dec. 18, 2017 — EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or […]

read more

EyeGate Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business Update

WALTHAM, Mass., Nov. 14, 2017 — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for […]

read more

EyeGate Completes Enrollment in Phase 2b Clinical Trial of EGP-437 for Cataract Surgery

Triggers Milestone Payment under Global Licensing Agreement with Valeant Pharmaceuticals WALTHAM, Mass., Nov. 08, 2017 — EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a […]

read more

EyeGate Appoints Mike Garanzini as Chief Commercial Officer to Develop and Implement Global Launch Strategy

A product marketing veteran with an ophthalmology focus at companies such as Santen, Merck and Pharmacia WALTHAM, Mass., Nov. 01, 2017 — EyeGate Pharmaceuticals, Inc. […]

read more

Eye Care Thought Leaders Join EyeGate Scientific Advisory Board

WALTHAM, Mass., Oct. 23, 2017 — EyeGate Pharmaceuticals, Inc. (EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company focused on developing and commercializing products […]

read more

EyeGate Launches Social Media Pages to Enhance Investor and Trade Relationships

WALTHAM, Mass., Sept. 11, 2017 — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or the “Company”), a clinical-stage specialty pharmaceutical company focused on developing and commercializing products […]

read more

EyeGate Pharma to Present at the 19th Annual Rodman and Renshaw Global Investment Conference

WALTHAM, Mass., Sept. 05, 2017 — EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage specialty pharmaceutical company focused on developing and commercializing products […]

read more

EyeGate Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Business Update

WALTHAM, Mass., Aug. 07, 2017 — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or the “Company”), a clinical-stage specialty pharmaceutical company that focuses on developing and commercializing […]

read more

EyeGate Pharma Enrolls First Patient in Phase 2b Clinical Study of EGP-437 for Cataract Surgery

WALTHAM, Mass., Aug. 01, 2017 — EyeGate Pharmaceuticals, Inc. (EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and commercializing products […]

read more